Picard Medical (PMI) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
10 Feb, 2026Executive summary
Special meeting scheduled for March 10, 2026, to be held online for increased participation.
Record date for voting is February 6, 2026, with 73,701,176 shares of common stock outstanding and entitled to vote.
Main purpose is to consider and vote on an amendment to increase authorized shares of capital stock and common stock.
Voting matters and shareholder proposals
Proposal to amend the Certificate of Incorporation to increase authorized capital stock from 180,000,000 to 330,000,000 and common stock from 150,000,000 to 300,000,000.
Board unanimously recommends voting FOR the proposal.
Voting can be done online, by phone, mail, or during the virtual meeting; proxies can be revoked before voting.
Abstentions count as votes against; broker non-votes have no effect.
Board may abandon the amendment even after approval if deemed not in the best interest of the company.
Shareholder rights and capital structure
Amendment would not affect authorized preferred stock, which remains at 30,000,000 shares.
Additional shares would have rights identical to current common stock; no preemptive rights for holders.
Increase in authorized shares could have anti-takeover effects, though not intended as such.
Issuance of new shares may dilute existing shareholders' equity and voting rights.
Board retains discretion to issue new shares without further shareholder approval, except as required by law or exchange rules.
Latest events from Picard Medical
- Approval sought for major share increase and new issuances to enable financing and NYSE compliance.PMI
Proxy Filing19 Feb 2026 - Vote proposed to double authorized common stock, supporting future capital needs and flexibility.PMI
Proxy Filing19 Feb 2026 - FDA-approved artificial heart maker registers 17M shares for resale amid ongoing losses and risks.PMI
Registration Filing4 Feb 2026 - Market leader advances total artificial heart tech, targeting global growth and next-gen innovation.PMI
H.C. Wainwright 27th Annual Global Investment Conference3 Feb 2026 - Resale of up to 17M shares may dilute holders as company seeks growth in artificial heart market.PMI
Registration Filing12 Jan 2026 - Vote to expand the equity plan and add warrants, supporting long-term talent retention.PMI
Proxy Filing2 Dec 2025 - Vote sought to expand equity plan to 18M shares and add warrants to attract and retain talent.PMI
Proxy Filing2 Dec 2025 - FDA-approved artificial heart leader seeks IPO to fund R&D, China JV, and address liquidity.PMI
Registration Filing29 Nov 2025 - FDA-approved artificial heart leader seeks IPO to fund R&D and global expansion amid ongoing losses.PMI
Registration Filing29 Nov 2025